Disclaimer: The medications discussed in this article may include compounded preparations from a licensed 503A compounding pharmacy. Compounded medications have not been reviewed or approved by the FDA and are not the same as commercially available FDA-approved products. This content is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Please consult a licensed healthcare provider for personalized clinical guidance.
Microdosing GLP-1 is the practice of taking semaglutide or tirzepatide at doses well below the approved maintenance range, usually with the goal of getting some appetite suppression without the side effects, keeping weight off after a larger loss, or chasing claimed benefits unrelated to weight. It has spread fast through social media and through clinics that see a cheaper, lower-commitment product to sell. What it does not have is a clinical trial. This article explains where the idea came from, what the dose-response data says, and why our providers approach it with care.
Where the Idea Came From
Three things converged. First, the approved titration schedules for these medications start low, which means everyone who has ever used one has experienced a low dose and remembers that it did something. Second, compounded vials made dose flexibility easy in a way that fixed-dose pens never did. Third, the cost of full-dose therapy pushed people to ask whether less would do.
The term itself is borrowed from psychedelics, where it means sub-perceptual doses. Applied to GLP-1 medications it is a marketing word, not a clinical one. No regulatory body, trial, or guideline defines it.
What the Dose-Response Data Shows
The closest thing to evidence is the dose-ranging research that preceded approval. A 2018 phase 2 trial in The Lancet tested five daily doses of semaglutide against placebo and liraglutide over 52 weeks in 957 adults with obesity. Weight loss was 6.0 percent at the lowest dose, 8.6 percent at the next, and 13.8 percent at the highest, against 2.3 percent for placebo.[1]
Two things follow from that. Low doses do produce weight loss, which is why microdosing feels like it works. And the effect is dose-dependent, which means a fraction of the dose gives you a fraction of the result, with the same gastrointestinal side effects appearing in proportion.[1] The trial did not test doses below its lowest arm, so anything smaller than that is outside the data entirely.
The Maintenance Argument
The strongest case for lower doses is maintenance after weight loss, and here the evidence cuts the other way. The STEP 4 trial took 803 participants who had reached the full 2.4 mg semaglutide dose and randomized them to continue or switch to placebo for 48 weeks. The group that continued lost a further 7.9 percent. The group that stopped regained 6.9 percent.[2]
That trial tested full dose versus nothing. It did not test a reduced maintenance dose, which is what microdosing advocates propose. So the accurate position is that we know stopping leads to regain, and we do not know whether a lower dose prevents it. It might. There is no trial that says so.
Why Our Providers Are Cautious
Four reasons.
There is no evidence base. Every dose decision our providers make is anchored to the trial-tested ranges, because those are the doses with known effects and known side-effect rates. Below that range, they are guessing, and so is everyone else.
Compounded products add variability. A compounded vial is drawn by the patient, which means the dose depends on reading a syringe correctly every week. At low volumes, small measurement errors become large percentage errors.
Off-label use of a compounded product for an unvalidated purpose stacks regulatory risk. The FDA has issued warning letters to telehealth companies over how compounded GLP-1 medications are marketed. “Microdosing” claims are exactly the kind of language that invites scrutiny.
The benefits people chase at microdoses, beyond appetite, are largely speculative. Anti-inflammatory effects, longevity, and “metabolic optimization” at sub-therapeutic doses are extrapolations from mechanism, not findings from trials.
What We Do Instead
Our providers prescribe within the ranges that have trial data and adjust within those ranges based on response and tolerability. A patient who does well at a lower approved dose stays there. A patient who has reached goal weight has a maintenance conversation that covers the STEP 4 data directly, including what we do not know.
We do not sell a microdosing product, and we will not until someone runs the trial. If you are considering it elsewhere, ask the clinic one question: what study supports the dose you are proposing? Listen for a specific answer.
To learn how our GLP-1 programs are structured, see our compounded semaglutide and compounded tirzepatide pages.
References
O’Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637-649. PubMed: 30122305
Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. PubMed: 33755728
This article is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Please consult a licensed healthcare provider for personalized guidance.
JP Rius is the founder of Precision Telemed. His perspective is shaped by the commercial, regulatory, and operational side of telehealth medicine.
